Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK
MENU
Back to Top

George Grossberg

George T. Grossberg, MD
(United States), Past President

George T. Grossberg, M.D. is the Samuel W. Fordyce Professor and Director of Geriatric Psychiatry at Saint Louis University School of Medicine. In 1979, he started the first Geriatric Psychiatry Program in Missouri and in 1985, the first Alzheimer’s disease Community Brain Bank.

Dr. Grossberg and his work have been featured in numerous national publications, including People magazine, Good Housekeeping, USA Today and the New York Times. He has appeared on many television programs including 48 Hours, CNN, Lifetime TV, and the Sally Jesse Raphael Show. Dr. Grossberg is a former President of the American Association of Geriatric Psychiatry and has been a leader in developing mental health programs, treatment and research in geriatrics. Dr. Grossberg has edited six textbooks and contributed over 300 articles, chapters and abstracts to the geriatric literature. He currently serves as Medical Editor of CNS/LTC, Assistant Editor of the International Journal of Geriatric Psychopharmacology and is on the editorial boards of the Journal of Clinical Psychiatry and Demencia Hoy.

Dr. Grossberg is a consultant to the pharmaceuticals industry in developing protocols for central nervous system disorders in the elderly and is involved in a variety of basic as well as clinical research projects in the area of dementing disorders with a focus on behavioral disturbances in dementia.

Dr. Grossberg has served as a consultant on nursing homes to the U.S. Justice Department Civil Rights Division and he chaired the development of Clinical Practice Guidelines for the Treatment of Depression in the Nursing Home for the American Medical Director’s Association and developed educational guidelines on Alzheimer’s disease for the American Academy of Family Practice.

Dr. Grossberg serves as a consultant to Abbott, Astra-Zeneca, Bayer, Forest, Janssen, Lilly, Novartis, Organon, Omnicare and Synthelabo. He is currently receiving research support from Abbott, Boehringer-Ingelheim, Eunoe, Forest, Glaxo/SmithKline, Janssen, Lilly, Novartis and Organon

Dr. Grossberg served on the Board of Directors from 1994-2007. He can be reached at Grossbgt@slu.edu.

Acknowledgements

Acadia Pharmaceuticals Axsome Cambridge University Press Cerevel Lundbeck Otsuka